Partners as of December 2023:

Health Equity *Hero*

CLINICAL TRIALS

Reflections

Create sustainable improvements in clinical trial diversity and inclusion through a first-of-its-kind, multi-sponsor, multi-advocacy organization collaboration

Why It Matters

Individuals representing diverse backgrounds, such as pregnant women, racial, ethnic, and LGBTQIA+ groups, have historically been under-represented in clinical trials for medical products. This lack of representation may lead to an incomplete understanding of the safety and efficacy of new treatments and limit the generalizability of trial findings.

In 2020, industry-sponsored clinical trials for FDA approval of new molecular entities and original therapeutic biologics included only 8% Black or African American, 6% Asian, and 11% Hispanic or Latino participants.

Many underserved communities may not even know they are underrepresented in research.

Solution

A local community-based program aimed at understanding, affecting, and improving various social and structural factors that impact clinical trial participation.
Program aims to increase recognition within diverse communities regarding:
- Underrepresentation in clinical research,
- Implications of underrepresentation,
- Solutions that support greater participation



Together with local advocacy chapters and health care institutions, broader topics and health related programs will be initiated to address local policies and the types of support needed to increase representation.

Impact

The program will launch in March 2024 and identify / measure:

- Improvements to enrollment rates in local clinical trials that represent disease demography
- Sustainability of increased and diverse clinical trial representation
- Improvements in literacy and trust related to clinical trials
- Programs needed to sustainably improve participation rates

Key Learnings

Improving diversity and inclusion in clinical trial participation requires commitment and willingness to try new approaches. Reflections is a pilot collaboration involving biopharmaceutical companies, advocacy groups, trial sites, and local stakeholders.

It is guided by PALADIN, a novel, pre-competitive, disease-agnostic membership community working together to create consensus-based resources, guidelines and solutions that will transform how patient advocacy groups, pharmaceutical and biotechnology companies collaborate in the future.